Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $210.00 at Needham & Company LLC

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price upped by equities research analysts at Needham & Company LLC from $205.00 to $210.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 46.58% from the company’s previous close.

A number of other research analysts also recently weighed in on JAZZ. Royal Bank of Canada restated an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. TD Cowen reduced their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $182.47.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $143.27 on Wednesday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $8.66 billion, a price-to-earnings ratio of 20.18, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The business has a 50-day simple moving average of $125.87 and a two-hundred day simple moving average of $118.62. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $148.06.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 5,053 shares of company stock worth $617,442 in the last three months. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in JAZZ. IFP Advisors Inc bought a new stake in Jazz Pharmaceuticals during the 4th quarter valued at approximately $25,000. Quadrant Capital Group LLC grew its holdings in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 101 shares in the last quarter. Elequin Capital LP raised its position in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 183 shares during the last quarter. CoreFirst Bank & Trust purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $28,000. Finally, Allianz SE bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $29,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.